What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Sarepta Therapeutics in a research note issued on Monday, November 25th. HC Wainwright analyst M. Kapoor forecasts that the biotechnology company will post earnings of $2.30 per share for the year. HC Wainwright has a “Sell” rating and a $80.00 price objective on the stock. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.07 per share. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.53 EPS, Q1 2025 earnings at $2.32 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.75 EPS, Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $10.58 EPS.

SRPT has been the topic of several other reports. Royal Bank of Canada restated an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Piper Sandler reduced their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Jefferies Financial Group began coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. Finally, Evercore ISI cut their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $176.73.

Sarepta Therapeutics Trading Up 13.8 %

NASDAQ SRPT opened at $130.50 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock’s 50-day moving average is $121.80 and its 200-day moving average is $131.40. Sarepta Therapeutics has a one year low of $78.67 and a one year high of $173.25. The firm has a market cap of $12.47 billion, a P/E ratio of 104.40 and a beta of 0.81.

Insider Buying and Selling

In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This trade represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 7.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the business. Innealta Capital LLC acquired a new position in shares of Sarepta Therapeutics in the second quarter valued at $31,000. New Covenant Trust Company N.A. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth about $32,000. Sunbelt Securities Inc. grew its stake in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 232 shares during the last quarter. Huntington National Bank grew its stake in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the last quarter. Finally, Nkcfo LLC acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $43,000. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.